8-K: Celcuity Reports Positive Phase 3 VIKTORIA-1 Trial Results

Celcuity announced that its Phase 3 VIKTORIA-1 trial met its primary endpoint, showing improved progression-free survival in PIK3CA mutant breast cancer patients.

Summary

• The Phase 3 VIKTORIA-1 trial evaluated gedatolisib plus fulvestrant, with or without palbociclib, in HR+/HER2metastatic breast cancer patients.
• The gedatolisib triplet regimen demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to alpelisib plus fulvestrant.
• The gedatolisib doublet regimen also showed a statistically significant and clinically meaningful improvement in PFS compared to the alpelisib control arm.
• Both gedatolisib regimens were reported as well-tolerated with manageable safety profiles and no new safety signals.
• The company plans to submit these data to the FDA as a supplemental New Drug Application (sNDA).

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive development, as the company successfully met primary and secondary endpoints in a Phase 3 trial against an established competitor, significantly de-risking the clinical program.

Positives

• Primary endpoint met with statistically significant improvement in PFS for the triplet regimen.
• Secondary endpoint met with statistically significant improvement in PFS for the doublet regimen.
• Gedatolisib demonstrated a manageable safety profile with no new safety signals observed.
• The trial results validate the company's approach to comprehensively blocking the PI3K/AKT/mTOR (PAM) pathway.

Negatives

• The company remains in a clinical-stage status without currently approved commercial products.
• The trial results are based on topline data, which are subject to change following a more comprehensive review.

Risks

• Topline clinical results may change following a more comprehensive review of the data.
• Potential for unforeseen delays in clinical trials or the FDA review process.
• Uncertainty regarding the ability to obtain and maintain regulatory approvals for commercialization.
• Risk of market acceptance for gedatolisib once commercialized.
• Competition from other therapies and tools currently in development.
• Potential difficulty in accessing capital upon favorable terms.

Future Outlook

The company intends to submit the VIKTORIA-1 data as an sNDA to the FDA and to other regulatory authorities, while continuing to explore the development of gedatolisib for additional patient groups involving the PAM pathway.

Management Comments

• VIKTORIA-1 represents the first Phase 3 study to demonstrate that comprehensively blocking the PAM pathway can significantly improve outcomes for patients with PIK3CA mutations.
• These positive topline results demonstrate the potential for gedatolisib to become a transformative new medicine for the treatment of patients with PIK3CA mutant HR+/HER2advanced breast cancer.
• The implications of these results may extend beyond HR+/HER2advanced breast cancer patients in the second-line setting.

Industry Context

StockSavvy.ai notes that this announcement positions Celcuity as a significant challenger to existing PI3K inhibitors like Novartis's Piqray (alpelisib). By demonstrating superior efficacy through comprehensive PAM pathway blockade, Celcuity is attempting to redefine the standard of care in the crowded HR+/HER2metastatic breast cancer market.

Comparison to Industry Standards

• The trial directly compared gedatolisib against alpelisib (Piqray), which is currently an FDA-approved standard of care for PIK3CA-mutant breast cancer.
• The study addresses the limitation of single-target inhibitors, which often face resistance due to cross-activation of the PAM pathway.

Stakeholder Impact

• Shareholders: Potential for increased valuation based on positive clinical data.
• Patients: Potential for a new, more effective treatment option for metastatic breast cancer.
• Competitors: Potential loss of market share for existing PI3K inhibitors.

Next Steps

• Present detailed data at the 2026 ASCO Annual Meeting.
• Submit supplemental New Drug Application (sNDA) to the FDA.
• Submit data to other international regulatory authorities.
• Continue ongoing VIKTORIA-2 and CELC-G-201 clinical trials.

Key Dates

Recommendation

The successful Phase 3 trial results provide a clear path to regulatory submission and potential commercialization, significantly increasing the intrinsic value of the company's lead asset, gedatolisib.

Keywords

Celcuity, Gedatolisib, VIKTORIA-1, Breast Cancer, Oncology, Biotechnology, PIK3CA, Clinical Trial